imc-f106c, a novel prame × cd3 immtac, in metastatic cutaneous melanoma
Published 5 months ago • 126 plays • Length 6:25Download video MP4
Download video MP3
Similar videos
-
2:43
phase i dose escalation of imc-f106c - first prame × cd3 immtac bispecific protein in solid tumors
-
2:55
melanoma trials at asco 2024: keymaker-u02a, imc-f106 and sc-682
-
2:39
tebentafusp in combination with durvalumab and/or tremelimumab in metastatic cutaneous melanoma
-
47:55
cutaneous melanoma surgical treatment 2022 update
-
1:18
melanoma metastases to ovary
-
31:14
early detection of melanoma
-
1:01:58
clinical trials 101
-
30:45
the role of prame immunohistochemistry in the diagnostic approach to melanocytic lesions
-
5:09
melanoma: investigations and oncology
-
0:48
targeting c/ebpβ in melanoma
-
19:27
stage ii cutaneous melanoma explained
-
21:57
current and emerging novel immunotherapies for myeloma
-
2:52
novel prognostic score for cmml patients undergoing sct
-
41:36
ac20 - ccf research fellowship reports part 2
-
35:58
melanoma and sarcoma – 12 may 2020
-
27:47
novel immunotherapies (car t, bispecifics, and adcs) - jeremy abramson, md
-
10:53
ac22 - deep immune profiling of intrahepatic cholangiocarcinoma with codex multiplexed imaging
-
29:04
melanoma update
-
57:59
critical values in cytology
-
25:34
novel immunotherapies and combinations